<DOC>
	<DOCNO>NCT00319800</DOCNO>
	<brief_summary>To determine whether docetaxel pretreated advanced NSCLC patient favorable clinical parameter ( ) gefitinib produce different outcome patient without favorable clinical parameter treat irinotecan .</brief_summary>
	<brief_title>Second-Line Irinotecan Gefitinib Docetaxel Pretreated NSCLC</brief_title>
	<detailed_description>It suggest clinical parameter , include woman , smoke history histologic diagnosis adenocarcinoma , associate favorable outcome gefitinib therapy . We conduct phase II study docetaxel pretreated advanced NSCLC patient treat gefitinib irinotecan accord clinical parameter order determine whether patient favorable clinical parameter ( ) gefitinib produce difference outcome patient without favorable clinical parameter treat irinotecan .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>age 75 year less histologically cytologically confirm nonsmall cell lung cancer advance , metastatic recurrent ECOG performance status 0 2 one prior palliative chemotherapy include docetaxel measurable evaluable indicator lesion ( ) normal marrow , hepatic renal function provision write informed consent active infection and/or severe comorbidities pregnant breastfed woman active CNS metastasis active bleeding GI tract elsewhere</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>